Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).